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Abstract 
Aim Splenectomy improves hypersplenic thrombocytopenia in cirrhotic patietnts with 
hypersplenism. However, the long term influence of splenectomy has not been calrified. We 
examined whether splenectomy improved liver fibrosis and casused immunological changes. 
Material and Methods We collected liver and spleen specimens and peripheral blood (PB) 
from 26 patients with hepatitis C virus (HCV)-related liver cirrhosis. An 
immunohistochemical examination of CD4, CD8, forkhead box P3 (FOXP3), granzyme B, 
and transforming growth factor (TGF)-β1, and Masson’s Trichrome stain were performed in 
spleen and liver tissues and in 7 cases of follow-up liver biopsy sections obtained after 
splenectomy. We obtained PB before and at various intervals after splenectomy. We also 
examined the ratio of CD4+ and CD8+ lymphocytes in PB using flow cytometry. Results We 
observed improvements in liver fibrosis in 4 biopsy specimens obtained after splenectomy, in 
which fibrotic areas significantly decreased from 19.5% to 8.2% (p<0.05). Increases were 
also observed in the ratio of CD8+ cells in PB after splenectomy, which resulted in a 
significant decrease in the CD4+/CD8+ ratio (p<0.001). The carcinogenic rate in patients with 
a CD4+/CD8+ ratio that decreased by more than 0.5 one month after splenectomy was 
significantly lower than that in patients with a ratio that decreased by less than 0.5 (p<0.05). 
Conclusions Splenectomy may improve liver fibrosis and cause beneficial immunological 
changes in cirrhotic patients with hepatitis. Improvements in anti-tumor mechanisms can be 
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also expected. 
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Introduction 
Splenectomy is a common treatment used to improve hypersplenic thrombocytopenia in 
cirrhotic patients with splenomegaly in Japan 1-7. Splenectomy has recently been applied as 
another option to cure hepatocellular carcinoma (HCC) and for cirrhotic patients with no 
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potential donor for liver transplantation. Thus, the clinical application of splenectomy has 
been expanded; however, the immunophysiology of the spleen in cirrhotic patients and the 
long term outcome after splenectomy have not been clarified 8-14. This study was designed to 
clarify the long term changes and prediction of HCC development following splenectomy, 
with a focus on hepatic fibrosis and immunology. Regarding hepatic fibrosis, Akahoshi et al 
reported that TGF-β1 derived from the spleen could have an inhibitory role in healing iver 
cirrhosis by inhibiting the regeneration of the damaged liver15 and we experimentally 
confirmed that splenectomy significantly reduced liver fibrosis and decreased TGF-β1 in the 
serum of a dimethylnitrosamine-induced cirrhotic rat model 16. However, no studies have yet 
described a reduction in hepatic fibrosis following splenectomy in humans. 
The spleen plays an important role in the immune response; however, the functional aspects 
of the spleen in cirrhotic patients with HCV infection are largely unknown 2, 17.  Hashimoto 
et al reported that splenectomy was followed by an increased ratio of interferon (IFN)-γ to 
interleukin (IL)-10 and a reduction in programmed death (PD)-1-expressing CD4+ T cells in 
PB 7. In order to clarify chronological changes in immunity after splenectomy, we examined 
liver and spleen tissues and sera to assess CD4+ and CD8+ cytotoxic T lymphocytes (CTLs), 
and regulatory T (Treg) cells 18, 19. TGF-β1 was also examined as it is a multifunctional 
cytokine that inhibits the growth of tumor cells 20-23 and liver regeneration by facilitating 
tissue fibrosis in the liver 16. 
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Host immunoreactions against cancer were shown to be closely related to cellular immunity 
by CD8+ CTLs and Treg cells, produced by T lymphocytes, and CD8+ CTLs in particular 19. 
The level of Treg cells, characterized by the expression of forkhead box P3 (FOXP3) 
transcription factor in the PB and tumor tissues of patients with HCC, was elevated and 
appeared to be negatively correlated with prognosis 21, 24, 25.  
In the present study, we examined whether splenectomy could improve liver fibrosis, cause 
immunological changes, especially in CTLs, or be used to predict the risk of carcinogenesis. 
 
 
 
 
 
 
 
 
Materials and methods 
1. Patients and samples (Table 1) 
At the Surgery Department of Kurume University Hospital, 26 patients (Child A; 16 cases, 
Child B, C; 10 cases) with HCV-related liver cirrhosis (with HCC; 7 cases, without HCC; 19 
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cases) and hypersplenism underwent splenectomy (splenectomy group). The purpose of 
splenectomy was to improve hypersplenic thrombocytopenia and introduce interferon for 
clearance of the HCV virus. Forty-eight patients who underwent hepatectomy due to liver 
tumors were recruited as controls (control group 1). PB samples from 10 healthy adult 
volunteers (control group 2) and spleen tissues obtained by splenectomy from 7 patients 
because of trauma (control group 3) were also used as controls. In addition, all patients were 
HIV-negative. Patients received no medical treatment except splenectomy during the study 
period. All samples were studied after obtaining the appropriate institutional informed 
consent. We also obtained permission from the Ethical Review Board. 
Liver tissue 
A total of 26 pieces from the resected liver specimens of patients with HCV-related liver 
cirrhosis and hypersplenism who underwent splenectomy were also examined for the 
immunohistochemical expression of CD4+ lymphocytes, CD8+ lymphocytes, FOXP3, 
granzyme B, and TGF-β1 positive cells (Fig. 1). We classified liver specimens into 5 stages 
according to the degree of fibrosis as follows: F0, no fibrosis in the portal tract; F1, portal 
fibrosis without septa; F2, portal fibrosis with a few septa; F3, numerous septa without 
cirrhosis; and F4, cirrhosis.  We collected resected liver specimens from 10 cases each of F1, 
F2, F3, and F4 with HCV-related liver disease. We also collected specimens from 8 cases of 
liver hemangioma of F0 with both negative HBs-Ag and HCV-Ab. Follow-up liver biopsy 
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sections were obtained from the same part of the liver if possible from 7 of the 26 patients at 
various intervals after splenectomy (Table 2). These sections were used for CD4 and CD8 
immunostaining and Masson’s Trichrome staining for the morphometric evaluation of fibrotic 
areas.  
Spleen tissue 
A total of 26 spleens with HCV-related liver cirrhosis and hypersplenism were examined for 
the immunohistochemical expression of CD4 positive lymphocytes, CD8 positive 
lymphocytes, FOXP3, granzyme B, and TGF-β1 positive cells. We measured the same 
parameters in spleens from the 7 control cases in control group 3 as a non-cirrhotic control 
(Fig. 1). Spleen and liver tissues were pathologically assessed by two pathologists (Y.N and 
M.K). 
Peripheral blood cells 
PB samples were serially collected from 26 patients with HCV-related liver cirrhosis and 
hypersplenism just before and 14 days, 1 month, 3 months, 6 months, and 1 year after 
splenectomy, respectively. We examined the ratio of CD4+ T cells to all lymphocytes, CD8+ T 
cells to all lymphocytes, and the CD4+/CD8+ ratio in PB samples using flow cytometry. And 
TGF-β1 levels in PB were also measured using enzyme-linked immunoassays in the sera just 
before and 14 days, 1 month, 3 months, 6 months, and 1 year after splenectomy, respectively. 
Patients were excluded from the protocol if IFN or other therapeutics were introduced for the 
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liver disease. Ten healthy adult volunteers in control group 2 without a history of liver disease 
or splenomegaly were also recruited as controls, and samples were collected only one time.  
 
2. Immunohistochemical analysis 
All fresh specimens were fixed by 10% formalin, and paraffin-embedded tissue samples were 
cut at a thickness of 4 μm, examined on a coated slide glass, and labeled with the following 
antibodies using the Bond-Max autostainer (Leica Microsystems, Newcastle, UK) and 
DAKO autostainer (DakoCytomation, Glostrup, Denmark): CD4 (×200, Leica Microsystems, 
Newcastle, UK): CD8 (×200, Leica Microsystems, Newcastle, UK), Granzyme B (×50, Leica 
Microsystems, Newcastle, UK), TGF-β1 (×300, Santa Cruz Biotechnology, Heidelberg, 
Germany), and Foxp3 (×600, Abcam Cambridge, USA).  
Immunohistochemical examinations with CD4, CD8, granzyme B, and TGF-β1 were 
performed on the same fully automated Bond-Max system using onboard heat-induced 
antigen retrieval with ER2 for 10 min and the Refine polymer detection system (Leica 
Microsystems, Newcastle, UK). DAB was used as the chromogen for all immunostaining. 
Foxp3 immunostaining was carried out using the DAKO autostainer with the ChemMate 
ENVISION method (DakoCytomation, Glostrup, Denmark). Briefly, specimens were boiled 
in a microwave for 30 min in 1 mmol/L EDTA, pH 9.0, and target retrieval solution 
(DakoCytomation, Glostrup, Denmark) to recover antigens, and the specimens were then 
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incubated with the antibody at 4°C overnight. After washing in tris-buffered saline (TBS), 
slides were incubated with the labeled polymer-HRP secondary antibody for 30 minutes at 
room temperature. After washing in TBS, slides were visualized using DAB. 
 
3. Detection of immune function using flow cytometry 
T lymphocyte subsets in PB such as CD4, CD8, and CD4/8 were determined by flow 
cytometry, and the monoclonal antibodies of CD4 and CD8 (labeled CD4-FITC, CD-8-RD1) 
were purchased from Beckman Coulter, USA.  
 
4．Result assessment 
Assessment criteria for lymphocytes and other positive cells counts: the number of 
lymphocytes and other positive cells were counted in 20 areas within a specimen under high 
power fields (x40 objective, x10 eyepiece). Ten areas of white and red pulp were assessed in 
the spleen, respectively, and 10 periportal areas and 10 hepatic lobule areas (Fig. 1) were 
assessed in a non-tumor area of the liver. 
Morphometric analysis (computer-image analysis) was performed in the following manner on 
specimens stained with Masson’s Trichrome. The equipment used to assess morphometry 
consisted of a light microscope, a three-color charge-coupled device camera, and a high 
resolution computer image-analysis system (WinRooF software package: version 6.1, Mitani 
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corporation, Fukui, Japan). The magnified images (40×) of specimens captured by the camera 
mounted on the microscope were sent to the image-analyzing computer. Collagen fibers 
stained with Masson’s Trichrome were then selected. In this study, this scanning procedure 
was repeated 10 times in random areas. The area of fibrosis (AF) was defined as the ratio (%) 
of the whole area of collagen fibers to that of the liver tissue scanned. 
 
5. Statistical analyses 
Statistical analysis was performed using the Student’s t test. A p-value of less than 0.05 was 
considered to be significant.  
The follow-up time was calculated as the interval between the date of surgery and 
intervention of the medical treatment, last follow-up, or recognition of HCC. Survival rates or 
failure rates were analyzed with the Kaplan-Meier method using the log-rank test to assess 
differences between curves. A p-value of less than 0.05 was considered to be significant. 
Statistical calculations were performed using the JMP software package (release 10, SAS 
Institute, Cary, NC, USA). 
Results 
1. Liver 
In the seven follow-up liver biopsy sections (Table 2) available for histological examination, 
liver fibrosis in the hepatic lobules improved from F4 to F3 in 4 cases (Cases 4-7: average, 
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268.5±168.6 days; range, 42-431 days) (Fig. 2-a). Improvements were not observed in the 
remaining 3 cases (Cases 1-3: average, 312±279.1 days; range, 24-581 days) (Fig. 2-b). There 
were no statistical differences in the duration between the improvement cases and 
non-improvement cases (p=0.80). Conducting an evaluation was difficult because only a few 
specimens were available; however, no significant differences in clinical profiles were 
observed among the 7 patients. In 4 of these cases (cases 4-7), the ratio significantly 
decreased from 19.5% to 8.2% (p<0.05) (Fig. 2-b), while the average AF in the remaining 3 
cases (cases 1-3) increased from 8.0% to 13.1% (p=0.15). The 4 cases of improved fibrosis 
were all Child-Pugh A, and one of the 3 cases that showed no improvement was Child-Pugh 
B. In addition, AF before splenectomy was slightly higher in the improvement cases than in 
the non-improvement cases, while the CD4+/CD8+ ratio before splenectomy was lower in the 
improvement cases than in the non-improvement cases (p<0.05). Histopathologically, CD4+ 
and CD8+ lymphocytes were mainly seen in the periportal area, and CD4+ lymphocytes were 
rarely seen in the hepatic lobules. The epithelial cells, fibroblasts, monocytes, and 
macrophages also produced TGF-β1 4, 21, 26. However, we picked up and counted the TGF-β1 
positive cells that were seen in the lymphocytes and found that these cells were distributed 
diffusely in the hepatic lobules and periportal area. The distribution pattern of Treg and 
granzyme B was the same as that of CD4+ and CD8+ lymphocytes, respectively. No 
significant differences were observed in the CD4+/CD8+ ratio (p=0.21) in liver specimens, 
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regardless of the association of HCC. The CD4+/CD8+ ratio (p<0.05) and Foxp3/CD4+ ratio 
(p<0.001) significantly increased with the progression of liver fibrosis (from F0 to F4). 
However, the granzyme B/ CD8+ ratio was approximately constant, and was unrelated to the 
progression of liver fibrosis (p=0.32). 
The number of TGF-β1 positive cells in livers with HCC was slightly higher than that in 
livers without (p=0.06), and the number of TGF-β1 positive cells also significantly increased 
with the progression of liver fibrosis (p<0.001) (Fig. 3). 
2. Spleen 
Histopathologically, CD4+ and CD8+ lymphocytes were found more in the white pulp than in 
the red pulp. The results of the clinicopathological analysis showed that the CD4+/CD8+ ratio 
in spleens with HCV-related liver cirrhosis and hypersplenism was higher than that in the 
spleens of control group 3 (p=0.06). The Foxp3/ CD4+ ratio in control group 3 was higher 
than that in cases of hypersplenism (p<0.05), and no significant differences in the granzyme 
B/ CD8+ ratio (p=0.82)were observed between the splenectomy group and control group 3 
(data not shown). 
3. Peripheral blood  
The ratio of CD4+ T cells to all lymphocytes and the CD4+/CD8+ ratio in PB samples 
obtained from 26 patients before splenectomy were significantly higher than those from 
control group 2 (p<0.01, p<0.05). In contrast, the ratio of CD4+ T cells to all lymphocytes 
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significantly decreased 1 year after splenectomy (p<0.001), while the ratio of CD8+ T cells to 
all lymphocytes slightly increased (p=0.07), resulting in a significant decrease in the 
CD4+/CD8+ ratio (p<0.001) (Fig. 4).  
TGF-β levels were higher in PB samples from patients with HCC than in those without. 
TGF-β1 levels slightly increased in PB samples 1 month after splenectomy, then decreased, 
and subsequently returned to the level measured before splenectomy in one year. 
4. Relationship of the CD4+/CD8+ ratio between PB and the spleen or liver 
In the splenectomy group, the CD4+/CD8+ ratio in PB had a significant positive correlation 
with the CD4+/CD8+ ratio in the spleen (p<0.05), and was also positively associated with the 
liver (p=0.07). As a result, a significant positive correlation was observed between the 
CD4+/CD8+ ratio in the spleen and that in the liver (p<0.05) (Fig. 5). 
5. Correlation between the CD4+/CD8+ ratio and clinical prognosis 
We compared the CD4+/CD8+ ratio between PB obtained pre-splenectomy and 1 month after 
splenectomy (n=19). The median of differences between pre-splenectomy and 1 month after 
splenectomy was 0.5. The occurrence of HCC was significantly lower in cases in which the 
difference in the CD4+/CD8+ ratio between the perioperative period and 1 month later was 
over 0.5 (>0.5 vs. <0.5, p<0.05) (Fig. 6A).  
A positive correlation in PB was observed between the CD4+/CD8+ ratio before splenectomy 
and differences in the CD4+/CD8+ ratio between pre-splenectomy and 1 month after 
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splenectomy (p<0.001). As the median of the preoperative CD4+/CD8+ ratio was 1.7, the 
postoperative (1 month after splenectomy) CD4+/CD8+ ratio significantly decreased in groups 
in which the preoperative value was larger than 1.7 (Fig. 6B, C). 
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Discussion 
Previous studies have shown that splenectomy was effective in improving pancytopenia, the 
decompression of portal hyperpressure, and liver function 1, 2, 27, 28. Morinaga et al reported 
that splenectomy significantly improved liver fibrosis with a reduction in plasma TGF-β1 
levels in the rat. However, all these reports of hepatic fibrosis were conducted in animal 
models 1, 16, 29, 30 whereas the present study described improvements in liver fibrosis after 
splenectomy in humans. Interestingly, the CD4+/CD8+ ratio changed after splenectomy 
without other treatment. However, many confounding factors may be implicated in this 
change. It is likely that patients with a high fibrotic area in their liver specimens had a high 
CD4+/CD8+ ratio; therefore, we may expect a decrease in the CD4+/CD8+ ratio after 
splenectomy. A decrease in Treg cells that stimulate TGF-β1 may lead to alleviation of 
fibrosis.  
 Because the immune function of CD4+ CTLs, CD8+ CTLs, and the CD4+/CD8+ ratio is 
affected by a wide variety of factors including recent exercise, poor nutrition, and coincident 
acute viral infections, it is difficult to evaluate immune function using only CD4+ CTLs, 
CD8+ CTLs, and the CD4+/CD8+ ratio. However, in our study, the ratio of CD4+ T cells to all 
lymphocytes in PB was significantly decreased in cirrhotic patients after splenectomy, while 
the ratio of CD8+ T cells to all lymphocytes slightly increased, resulting in a significant 
decrease in the CD4+ /CD8+ ratio. The CD4+/CD8+ ratios in PB, spleens, and livers were 
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significantly higher in patients with hypersplenism and in those in whom liver fibrosis had 
progressed than in the controls. As a positive correlation was observed between the 
CD4+/CD8+ ratios in the spleens, livers, and PB, it is possible to expect to predict the 
immunological state of the liver and spleen from the immunological state of PB. In addition, 
carcinogenesis was significantly lower in groups in which a large difference in the 
CD4+/CD8+ ratio was observed between before and after splenectomy or in those with a high 
CD4+/CD8+ ratio before splenectomy though there were few cases that we could observed. 
The CD4+ /CD8+ ratio is likely to be a key parameter for appropriate TIL function, and was 
shown to be different in different types of cancer 2, 31-35. Host immune responses to cancer 
were reported to depend on T lymphocytes, particularly CD8+ lymphocytes 18, 19, 24, 36-39. An 
increase in their ratio after splenectomy and the consequent decrease in the CD4+/CD8+ ratio 
observed in this study may be a positive change in terms of immunology against HCC. Such 
a change was particularly marked in patients with a high CD4+/CD8+ ratio before 
splenectomy. 
In our study, the CD4+ /CD8+ ratio also significantly increased as the fibrosis of non-tumor 
areas in the liver tissue progressed. These significant differences were observed regardless of 
the HCC status. Although the cause of these differences is unknown, it appears to depend on 
the background of histological factors in the liver such as fibrosis. Many studies have 
investigated the relationship between tumors, Treg, and TGF-β 20-22, 25, 40. Guo-He et al 
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showed that the expression of TGF-β appeared to be positively correlated with Treg in HCC 
tissue. The 5-year survival rate was significantly lower in patients with HCC tissues with 
high Treg cell infiltration than in those with low infiltration 20, 22, 36, 41. Our study also 
revealed that Treg cells were positively correlated with TGF-β1 positive cells even in 
“non-tumor areas” of liver tissue, and that TGF-β1 positive cells were positively correlated 
with liver fibrosis. There were no significant differences of TGF-β1 before and after 
splenectomy. The reason for the chronological changes in TGF-β1 levels after splenectomy is 
unknown because various factors including platelets may be involved in the production of 
TGF-β1. We also found a slightly higher number of TGF-β1 positive cells in non-tumor areas 
in the liver tissue of patients with HCC than in those without. Furthermore, the number of 
TGF-β1 positive cells significantly increased with the progression of liver fibrosis 4, 21, 26, 42.  
In conclusion, splenectomy in cirrhotic patients with hepatitis may be able to improve liver 
fibrosis, may cause beneficial immunological changes, and may lower the risk of 
carcinogenesis. It seems necessary to accumulate furthermore cases for convinced 
conclusion. 
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Figure legends 
 
Fig. 1 Immunohistochemical staining of spleen and liver specimens with FOXP3, CD4, CD8, 
granzyme B, and TGF-β1 in the spleen and liver. 
 
Fig. 2-a Improvements in liver fibrosis.  
Distortions in hepatic lobules improved in the liver biopsy sections of 4 cases after 
splenectomy, and fibrotic areas significantly decreased from 19.5% to 8.2% in these 
sections.  
 
Fig. 2-b Changes in the fibrotic areas of 7 patients at various intervals.  
    shows patients in whom  the fibrotic area significantly decreased after 
splenectomy. 
 shows patients in whom fibrosis deteriorated. 
 
Fig. 3  Correlation between TGF-β1 positive cells and fibrosis in the liver.  
The number of TGF-β1 positive cells also significantly increased with the progression of  
Liver fibrosis 
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Fig. 4 Changes in peripheral blood after splenectomy.  
(pre, preoperative; d, days; M, months; y, year)  
The ratio of CD4+ T cells to all lymphocytes significantly decreased 1 year after splenectomy, 
while the ratio of CD8+ T cells to all lymphocytes slightly increased, resulting in a 
significant decrease in the CD4+/CD8+ ratio. 
 
Fig. 5 Correlations between the CD4 + /CD8 + ratios in the spleen, liver, and PB.  
A significant positive correlation was observed between the CD4+/ CD8+ ratio in the spleen  
and that in the liver. 
 
Fig. 6A Correlation between carcinogenesis, the perioperative period, and 1 month later.  
The occurrence of HCC was significantly lower in cases in which the difference in the  
CD4+/CD8+ ratio between the perioperative period and 1 month later was over 0.5. 
 
Fig. 6 B, C Correlation in PB between the CD4 + /CD8 + ratio before surgery and differences  
in the CD4 + /CD8 + ratios before splenectomy and 1 month after splenectomy.  
B) A positive correlation in PB was observed between the CD4+/ CD8+ ratio before  
splenectomy and differences in the CD4+/CD8+ ratio between pre-splenectomy and 1 month  
after splenectomy.  
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C) The postoperative (1 month after splenectomy) CD4+/CD8+ ratio significantly decreased  
in groups in which the preoperative value was larger than 1.7 
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Fig. 1 
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Fig.2-a 
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Fig. 2-b 
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Fig.3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
 
 
Fig. 4 
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Fig. 5 
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Fig.6A 
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Fig. 6B, C 
 
